medigraphic.com
ISSN 1527-3172 (Digital)

2018, Número 3

<< Anterior Siguiente >>

MEDICC Review 2018; 20 (3)


Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba

Ochoa-Azze RF, García-Imía L, Vérez-Bencomo V

Idioma: Ingles.
Referencias bibliográficas: 40
Paginas: 22-29
Archivo PDF: 184.26 Kb.


RESUMEN

No abstract.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Oviedo-Orta E, Ahmed S, Rappuoli R, Black S. Prevention and control of meningococcal outbreaks: the emerging role of serogroup B meningococcal vaccines. Vaccine. 2015 Jul 17;33(31):3628–35.

  2. Sotolongo F, Campa C, Casanueva V, Fajardo EM, Cuevas IE, González N. Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application. MEDICC Rev. 2007 Oct;9(1):16–22.

  3. Ochoa RF, Sierra G. Vacunas contra la enfermedad meningocócica. In: Ochoa RF, Menéndez J, editors. Prevención de la enfermedad meningocócica. 1st ed. Havana: Finlay Ediciones; 2010. p. 67–84. Spanish.

  4. Borrow R, Lee JS, Vázquez JA, Enwere G, Taha MK, Kamiya H, et al. Meningococcal disease in the Asia–Pacifi c region: Findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016 Nov 21;34(48):5855–62.

  5. Ahmed SS, Oviedo-Orta E, Mekaru SR, Freifeld CC, Tougas G, Brownstein JS. Surveillance for Neisseria meningitidis disease activity and transmission using information technology. PLoS One [Internet]. 2015 May 20 [cited 2017 Mar 24];10(5):e0127406. Available from: http:// dx.plos.org/10.1371/journal.pone.0127406

  6. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr [Internet]. 2013 Sep 10 [cited 2017 Mar 24];11(1):17. Available from: https://pophealthmetrics.biomedcentral.com/ articles/10.1186/1478-7954-11-17

  7. Sridhar S, Greenwood B, Head Ch, Plotkin SA, Sáfadi MA, Saha S, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015 Nov;15(11):1334–46.

  8. Bianchi A, Fantoni S, Prugnola A. Meningococcal B vaccine and the vision of a meningitis free world. J Prev Med Hyg. 2015 Aug 31;56(3):E140–3.

  9. McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against Meningococcal disease. Microbiol Mol Biol Rev. 2013 Jun;77(2):234–52.

  10. Vermont C, van den Dobbelsteen G. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89–96.

  11. Centers for Disease Control and Prevention. Serogroup B meningococcal disease— Oregon, 1994. Morb Mortal Wkly Rep. 1995 Feb 24;44(7):121–4.

  12. Sierra GV, Campa HC, Valcárcel NM, García IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991 Dec;14(2):195–207.

  13. Uli L, Castellanos-Serra L, Betancourt L, Domínguez F, Barberá R, Sotolongo F, et al. Outer membrane vesicles of the VAMENGOC- BC® vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2006 Jun;6(11):3389–99.

  14. Gil J, Betancourt LH, Sardiñas G, Yero D, Niebla O, Delgado M, et al. Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens. Hum Vaccine. 2009 May;5(5):347–56.

  15. Williams JN, Weynants V, Poolman JT, Heckels JE, Christodoulides M. Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifi es potential cross-reactive antigens. Vaccine. 2014 Mar 5;32(11):1280–6.

  16. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine effectiveness in the fi eld. Further observations. Epidemiol Rev. 1988 Jan 1;10(1):212–41.

  17. Pérez Rodríguez A, Dickinson Meneses F, Rodríguez Ortega M. Efectividad de la vacuna antimeningocócica VA-MENGOC-BC® en el primer año de vida, Cuba, 1997–2008. Rev Cubana Med Trop. 2011 May–Aug;63(2):155–60. Spanish.

  18. Martínez Motas I, Sierra González G, Núñez Gutiérrez N, Izquierdo Pérez L, Climent Ruiz Y, Mirabal Sosa M. Caracterización de cepas de Neisseria meningitidis aisladas de portadores en Cuba durante 20 años. Rev Cubana Med Trop. 2006 May–Aug;58(2):124–33. Spanish.

  19. Climent Y, Yero D, Martínez I, Martín A, Jolley KA, Sotolongo F, et al. Clonal distribution of diseaseassociated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J Clin Microbiol. 2010 Mar;48(3):802–10.

  20. Climent Y, Urwin R, Yero D, Martínez I, Martín A, Sotolongo F, et al. The genetic structure of Neisseria meningitidis populations in Cuba before and after the introduction of a serogroup BC vaccine. Infect Genet Evol. 2010 May;10(4):546–54.

  21. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective effi cacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992 Oct 31;340(8827):1074–8.

  22. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol. 1995 Oct;24(5):1050–7.

  23. Costa EA, Martins H, Klein CH. Avaliação da proteção conferida pela vacina antimeningocócica BC no Estado de Santa Catarina, Brazil, 1990/92. Rev Saúde Pública. 1996 Apr;30(5):460–70. Portuguese.

  24. Galeano LA, Echeverry ML. Efectividad de una vacuna antimeningocóccica en una cohorte de Itaguí, Colombia, 1995. Bol Epidemiol Antioquia. 1995;20(2):110–8. Spanish.

  25. Costa EA. On the Controversy about the effectiveness of the antimeningococcal B vaccine: methodological pitfalls. Cad Saúde Pública. 1995 Apr–Jun;11(2):332–5.

  26. Echeverry Uribe ML, Malberty Agüero JA, Galeano Marín LA, Sotolongo Padrón FT, Galguera Domínguez MA, Montoya Barrientos CM, et al. Respuesta inmune humoral a las proteínas de una vacuna antimeningocócica BC en un ensayo realizado en Antioquia, Colombia. Bol Ofi cina Sanit Panam. 1995 Apr;118(4):285–94. Spanish.

  27. Pírez MC, Picón T, Galazka J, Rubio I, Montano A, Ferrari AM. Control de un brote epidémico de enfermedad meningocócica por Neisseria meningitidis serogrupo B. Rev Méd Urug. 2004 Aug;20(2):92–101. Spanish.

  28. Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J. 2001 Nov;20(11):1054–61.

  29. Camaraza MA, Ochoa R, Arnet A, Sotolongo F, Martínez I, Cuevas I, et al. Inmunogenicidad inducida por la vacuna antimeningocócica VAMENGOC- BC® contra la cepa de N meningitidis ATCC C11 en adolescentes después de 12 años de vacunados. Rev Cubana Med Trop. 2004 Jan–Apr;56(1):26–30. Spanish.

  30. Echeverry Uribe ML, Malberty Agüero JA, Galeano Marín LA, Sotolongo Padrón FT, Galguera MA, Montoya CM, et al. Respuesta inmune humoral al polisacárido capsular de Neisseria meningitidis serogrupo C en un ensayo de vacunación antimeningocócica BC en Antioquia, Colombia. Bol Ofi cina Sanit Panam. 1995 Apr;118(4):295–301. Spanish.

  31. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines–an unfi nished story. Lancet Infect Dis. 2010 Feb;10(2):112–24.

  32. Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccines in children aged under 5 years. Int J Epidemiol. 2009 Apr;38(2):413–8.

  33. Boutriau D, Poolman J, Borrow R, Findlow J, Diez-Domingo J, Puig-Barbera J, et al. Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol. 2007 Jan;14(1):65–73.

  34. Biblioteca Virtual en Salud de Cuba [Internet]. Havana: Ministry of Public Health (CU); c2018. Anuario Estadístico de Cuba; [cited 2017 Feb 17]; [about 1 screen]. Available from: http:// bvscuba.sld.cu/anuario-estadistico-de-cuba/. Spanish.

  35. Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012 Feb 18;379(9816):617–24.

  36. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B Meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012 Feb 8;307(6):573–82.

  37. Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, et al. Meningococcal serogroup B vaccines: Estimating breadth of coverage. Hum Vaccin Immunother. 2017 Feb;13(2):255–65.

  38. Basta NE, Mahmoud AAF, Wolfson J, Ploss A, Heller BL, Hanna S, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016 Jul 21;375(3):220–8.

  39. Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazaz R, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017 Jan 11;35(3):427–34.

  40. Pérez O, Lastre M, Lapinet J, Bracho G, Díaz M, Zayas C, et al. Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-Meningococcal BC vaccine. Infect Immun. 2001 Jul;69(7):4502–8.




2020     |     www.medigraphic.com